UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000009171 |
|---|---|
| Receipt number | R000010761 |
| Scientific Title | Analysis of efficacy and safety of antiviral therapy with telaprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantation |
| Date of disclosure of the study information | 2012/10/23 |
| Last modified on | 2012/10/23 13:47:38 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Analysis of efficacy and safety of antiviral therapy with telaprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantation
Acronym
Triple therapy for posttransplant hepatitis C
Scientific Title
Analysis of efficacy and safety of antiviral therapy with telaprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantation
Scientific Title:Acronym
Triple therapy for posttransplant hepatitis C
Region
| Japan |
Condition
Condition
hepatitis C after liver transplantation
Classification by specialty
| Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery | Adult |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
To clarify the efficacy and safety of antiviral therapy with telaprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantation
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Efficacy and safety of antiviral therapy with telaprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantation
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Recurrent hepatitis C after liver transplantation
2. HCV genotype 1
3. 20 years old and over
4. Possible to come to Kyoto University Hospital during the treatment
5. Written informed consent for participation in this study is obtained
Key exclusion criteria
without abilty to understand informed consent
Target sample size
20
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yoshihide Ueda |
Organization
Kyoto University Hospital
Division name
Gastroenterology and Hepatology
Zip code
Address
54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
TEL
075-751-4319
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name |
Organization
Kyoto University Hospital
Division name
Gastroenterology and Hepatology
Zip code
Address
54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
TEL
Homepage URL
Sponsor or person
Institute
Kyoto University Hospital
Institute
Department
Personal name
Funding Source
Organization
none
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 10 | Month | 23 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2012 | Year | 06 | Month | 04 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 10 | Month | 23 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
We will observe the efficacy and safety of anti-viral therapy with telaprevir, peginterferon and ribavirin for recurrent hepatitis C after liver transplantation in Kyoto University, and analyze teh predictive factors of the efficacy and safety.
Management information
Registered date
| 2012 | Year | 10 | Month | 23 | Day |
Last modified on
| 2012 | Year | 10 | Month | 23 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010761
